Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GPR3 | P46089 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.42 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13841330 | 0.84 | GPR3 (0.45) | GPR3WDR5FFAR4BCL2L1IL1B | |
| SCHEMBL7887616 | 0.82 | ESR1 (0.52) | ESR1TP53TDP1ESR2AR | |
| SCHEMBL24445841 | 0.81 | GPR3 (0.48) | TP53GPR3WDR5SCN5AMAPT | |
| SCHEMBL30867033 | 0.81 | GPR3 (0.49) | TP53TDP1GPR3FFAR4SCN5A | |
| SCHEMBL171112 | 0.81 | GPR3 (0.49) | TP53TDP1GPR3FFAR4SCN5A | |
| SCHEMBL102305 | 0.81 | ALDH1A1 (0.56) | WDR5MAPT | |
| SCHEMBL27396817 | 0.80 | GPR3 (0.44) | GPR3ARWDR5SCN5AMAPT | |
| SCHEMBL9368276 | 0.79 | LMNA (0.46) | ESR1TP53TDP1ESR2AR | |
| SCHEMBL14534817 | 0.78 | GPR3 (0.46) | GPR3FFAR4SCN5A | |
| SCHEMBL901107 | 0.78 | GPR3 (0.46) | GPR3FFAR4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903239-B2 | Fluorinated benzaldehydes | BAYER CHEMICAL AKTIENGESELLSCHAFT (DE) | 2005-06-07 | — | — | US | claimed |
| US-20040133043-A1 | Fluorinated benzaldehydes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | claimed |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| CN-116655497-B | Amidine derivative compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-06-03 | — | — | CN | disclosed |
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-05-01 | — | — | US | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | LIEBER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4476222-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| US-6903239-B2 | Fluorinated benzaldehydes | BAYER CHEMICAL AKTIENGESELLSCHAFT (DE) | 2005-06-07 | — | — | US | disclosed |
| US-20040133043-A1 | Fluorinated benzaldehydes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| EP-1428814-A1 | Fluorine containing benzaldehydes | Bayer Chemicals AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| EP-0365915-B1 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1994-04-20 | — | — | EP | disclosed |
| US-4956370-A | FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-09-11 | — | — | US | disclosed |
| EP-0368008-A1 | Fluorine-containing phenols | BAYER AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| EP-0365915-A2 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | ESR1 2536/4885TP53 3777/4885TDP1 4621/4885 |
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | RXFP3, RXFP4, RXFP2 | ESR1 570/4885TP53 3681/4885TDP1 4161/4885 |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | SCN8A, SCN1A, SCN2A | ESR1 4507/4885TP53 4755/4885TDP1 1487/4885 |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN1B | ESR1 4697/4885TP53 4854/4885TDP1 2228/4885 |
| US-20040133043-A1 | Fluorinated benzaldehydes | PFAS, FIP1L1, AFF2 | ESR1 3560/4885TP53 1464/4885TDP1 3456/4885 |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | ESR1 4407/4885TP53 4840/4885TDP1 3674/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | ESR1 4407/4885TP53 4840/4885TDP1 3674/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | ESR1 4407/4885TP53 4840/4885TDP1 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.